Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 28 peer-reviewed journal articles Updated
Cardiology

When Is an ICD Required for Brugada Syndrome?

At a Glance

An implantable cardioverter-defibrillator (ICD) is required for high-risk Brugada syndrome patients, such as those who have survived sudden cardiac arrest or have unexplained fainting with a spontaneous Type 1 ECG. Lower-risk patients typically manage the condition with lifestyle changes instead.

In this answer

4 sections

01

The High-Risk Criteria: When an ICD is Necessary

02

Evaluating Intermediate and Low-Risk Patients

03

Why Not Give an ICD to Everyone?

04

Alternatives and Add-Ons to an ICD

An implantable cardioverter-defibrillator (ICD) is the primary safeguard against sudden cardiac arrest in Brugada syndrome. However, not everyone with the condition needs one. Doctors reserve ICDs for patients they identify as “high risk,” based primarily on whether they have already experienced serious heart rhythm events or if they have specific combinations of symptoms and electrocardiogram (ECG) results. For patients at lower risk—who have never had symptoms—an ICD is rarely the first step, and lifestyle management is typically recommended instead.

The High-Risk Criteria: When an ICD is Necessary

Medical guidelines strongly recommend an ICD for individuals who have already survived a sudden cardiac arrest or have documented episodes of sustained ventricular tachycardia (a dangerously fast heart rhythm originating in the lower chambers) [1][2][3]. For these patients, the ICD serves as a critical, life-saving backup.

Doctors also typically recommend an ICD if a patient has experienced unexplained fainting, known as syncope, combined with a “spontaneous” Type 1 Brugada ECG pattern [4][5][6]. A spontaneous pattern means the characteristic Brugada wave shows up on a standard ECG naturally, without the need for high fever or specialized medications to trigger it [7][8]. The combination of unexplained fainting and a spontaneous Type 1 pattern is an established marker that a person is at a higher risk for future arrhythmias [7][8].

Evaluating Intermediate and Low-Risk Patients

For patients who have a spontaneous Type 1 ECG pattern but have never experienced any symptoms (like fainting or cardiac arrest), the decision becomes much more complex [5][9]. In these asymptomatic cases, an ICD might be considered, but it is not automatically required.

To help make this decision, a doctor might suggest an electrophysiology study (EPS). During this test, a specialist attempts to safely induce an abnormal heart rhythm in a controlled setting. If a dangerous rhythm is triggered (inducible), the doctor may recommend an ICD [10][11]. However, the reliability of the EPS is a subject of ongoing debate among international cardiology experts, as some studies suggest that a negative test does not guarantee a low risk of future events [10][12].

Doctors may also use risk-scoring systems like the Shanghai or Sieira scores, which look at family history, genetic testing (such as mutations in the SCN5A gene), and clinical history to estimate a person’s risk level [4][13][14]. Though helpful, these scoring models are not perfect and are used as pieces of a larger puzzle [15][16].

Why Not Give an ICD to Everyone?

If an ICD is a life-saving device, it is natural to wonder why it isn’t given to everyone diagnosed with Brugada syndrome. The main reason is that while an ICD is highly effective at stopping dangerous arrhythmias, it carries significant risks [17][18].

One of the biggest concerns is the risk of an “inappropriate shock”—where the device misinterprets a normal heart rhythm or benign electrical interference and delivers a painful shock when it isn’t needed [17][18]. Because many people diagnosed with Brugada syndrome are young and otherwise healthy, the lifetime risk of device complications (like wire fractures or infections) and inappropriate shocks is high [19][18]. To help mitigate some of these hardware complications, doctors increasingly use subcutaneous ICDs (S-ICDs), which are placed entirely under the skin rather than inside the heart, though they are not suitable for everyone [19]. For low-risk patients, the potential harm of having any device often outweighs the preventative benefits.

Alternatives and Add-Ons to an ICD

While an ICD remains the primary recommendation for high-risk patients, epicardial catheter ablation—a procedure that carefully targets and neutralizes the specific heart tissue causing abnormal electrical signals—is another option [20][21]. It is primarily used as an “add-on” therapy to reduce shocks for patients who already have an ICD, or as an alternative for those who absolutely cannot have or refuse the implant [22][23].

Additionally, the medication quinidine is an antiarrhythmic drug that is frequently used to help manage the condition and prevent arrhythmias, especially in patients experiencing frequent ICD shocks or who cannot undergo an implant [24][25][26].

Ultimately, for those in the low-risk category, the primary management strategy relies on strict lifestyle modifications. This involves aggressively treating fevers over 100.4°F (38°C) with medications like acetaminophen, as high body temperatures can unmask the Brugada pattern and trigger arrhythmias [27]. It also requires strictly avoiding medications known to interfere with the heart’s electrical system; doctors will provide guidance, and patients are internationally directed to use BrugadaDrugs.org as a standard reference before taking any new medication, including over-the-counter remedies [27][28].

Common questions in this guide

What makes someone high risk for needing an ICD with Brugada syndrome?
Patients are considered high risk if they have survived a sudden cardiac arrest, experienced dangerously fast heart rhythms, or have a combination of unexplained fainting and a spontaneous Type 1 Brugada ECG pattern.
Why doesn't everyone with Brugada syndrome get an ICD?
While an ICD is life-saving, it carries risks such as inappropriate shocks and hardware complications. Because many people with Brugada syndrome are young and otherwise healthy, doctors only recommend ICDs when the protective benefits outweigh these risks.
What is an electrophysiology study (EPS) used for in Brugada syndrome?
An EPS is a test where a specialist tries to safely trigger an abnormal heart rhythm in a controlled setting. It is sometimes used for patients with no symptoms to help determine if their risk is high enough to warrant an ICD.
Are there alternatives to an ICD for managing Brugada syndrome?
For high-risk patients, an ICD is the primary safeguard. However, treatments like epicardial catheter ablation or the medication quinidine can be used as add-ons to reduce ICD shocks, or as alternatives for those who absolutely cannot have the implant.
How is Brugada syndrome managed if an ICD is not required?
Low-risk patients usually rely on strict lifestyle modifications. This involves aggressively treating fevers over 100.4°F with acetaminophen and avoiding any medications known to interfere with the heart's electrical system.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my ECGs and symptom history, how do you categorize my current risk level for sudden cardiac arrest?
  2. 2.Has my Type 1 Brugada pattern been spontaneous, or was it only induced by fever or medication?
  3. 3.Do you recommend an electrophysiology study (EPS) for my specific case, and how would the results change my treatment plan?
  4. 4.If I am in a 'gray area' for an ICD, what specific symptoms or changes should prompt us to reconsider the implant?
  5. 5.If an ICD is recommended, am I a candidate for a subcutaneous ICD (S-ICD), and what are the pros and cons for my specific case?
  6. 6.Can you provide me with a comprehensive list of medications I need to avoid, and how should I handle over-the-counter cold medicines?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Positive Brugada Gene With No Symptoms: What Is The Risk?Why Does Brugada Syndrome Cause Agonal Breathing at Night?What Dental Anesthesia is Safe for Brugada Syndrome?What Do Brugada ECG Type 1 and Type 2 Mean?Is Epicardial Ablation a Cure for Brugada Syndrome?Brugada Fainting vs Vasovagal Syncope: How to Tell?What to Do for a Fever With Brugada SyndromeCan a Heavy Meal Trigger a Brugada Syndrome Episode?What Happens During a Brugada Provocation Test?Brugada Syndrome vs. SUNDS: Are They the Same?Can You Drink Alcohol With Brugada Syndrome?Can I Exercise With Brugada Syndrome? Safety GuideHow to Check Medication Safety Using BrugadaDrugs.orgIs Brugada Syndrome Hereditary? | Inciteful MedWhat Is a Molecular Autopsy for Brugada Syndrome?Why is Quinidine Used for Brugada Syndrome?How Is the Shanghai Score for Brugada Syndrome Calculated?What is a Brugada Phenocopy? ECG Pattern Explained

References

References (28)
  1. 1

    Implantable cardioverter-defibrillator in Brugada syndrome: Long-term follow-up.

    El-Battrawy I, Roterberg G, Liebe V, et al.

    Clinical cardiology 2019; (42(10)):958-965 doi:10.1002/clc.23247.

    PMID: 31441080
  2. 2

    Tpeak-Tend, Tpeak-Tend/QT ratio and Tpeak-Tend dispersion for risk stratification in Brugada Syndrome: A systematic review and meta-analysis.

    Tse G, Gong M, Li CKH, et al.

    Journal of arrhythmia 2018; (34(6)):587-597 doi:10.1002/joa3.12118.

    PMID: 30555602
  3. 3

    Meta-Analysis of Clinical Outcome After Implantable Cardioverter-Defibrillator Implantation in Patients With Brugada Syndrome.

    Dereci A, Yap SC, Schinkel AFL

    JACC. Clinical electrophysiology 2019; (5(2)):141-148 doi:10.1016/j.jacep.2018.09.005.

    PMID: 30784682
  4. 4

    Risk stratification of sudden cardiac death in Brugada syndrome: an updated review of literature.

    Darar C, Mohammed EA, Mohammed B, et al.

    The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology 2022; (74(1)):25 doi:10.1186/s43044-022-00267-9.

    PMID: 35404008
  5. 5

    Brugada syndrome: Diagnosis, risk stratification and management.

    Gourraud JB, Barc J, Thollet A, et al.

    Archives of cardiovascular diseases 2017; (110(3)):188-195 doi:10.1016/j.acvd.2016.09.009.

    PMID: 28139454
  6. 6

    Brugada syndrome in children - Stepping into unchartered territory.

    Behere SP, Weindling SN

    Annals of pediatric cardiology 2017; (10(3)):248-258 doi:10.4103/apc.APC_49_17.

    PMID: 28928611
  7. 7

    Time-to-first appropriate shock in patients implanted prophylactically with an implantable cardioverter-defibrillator: data from the Survey on Arrhythmic Events in BRUgada Syndrome (SABRUS).

    Milman A, Hochstadt A, Andorin A, et al.

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2019; (21(5)):796-802 doi:10.1093/europace/euy301.

    PMID: 30590530
  8. 8

    Risk factors for cardiac events in patients with Brugada syndrome: A PRISMA-compliant meta-analysis and systematic review.

    Wu W, Tian L, Ke J, et al.

    Medicine 2016; (95(30)):e4214 doi:10.1097/MD.0000000000004214.

    PMID: 27472692
  9. 9

    Quinidine in Brugada Syndrome: Still a Long Way to Go….

    Probst V, Gourraud JB

    Circulation. Arrhythmia and electrophysiology 2015; (8(6)):1309-10 doi:10.1161/CIRCEP.115.003576.

    PMID: 26671933
  10. 10

    The Role of Electrophysiological Study in the Risk Stratification of Brugada Syndrome.

    Bazoukis G, Chung CT, Vassiliou VS, et al.

    Cardiology in review 2023; doi:10.1097/CRD.0000000000000561.

    PMID: 37126436
  11. 11

    2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.

    Al-Khatib SM, Stevenson WG, Ackerman MJ, et al.

    Circulation 2018; (138(13)):e272-e391 doi:10.1161/CIR.0000000000000549.

    PMID: 29084731
  12. 12

    Programmed Ventricular Stimulation for Risk Stratification in the Brugada Syndrome: A Pooled Analysis.

    Sroubek J, Probst V, Mazzanti A, et al.

    Circulation 2016; (133(7)):622-30 doi:10.1161/CIRCULATIONAHA.115.017885.

    PMID: 26797467
  13. 13

    Unmasking a Silent Killer and Understanding Sudden Cardiac Death in Brugada Syndrome: A Traditional Review.

    Moturu A, Bhuchakra HP, Bodar YP, et al.

    Cureus 2023; (15(6)):e41076 doi:10.7759/cureus.41076.

    PMID: 37519561
  14. 14

    Predictive value of Shanghai score system in patients with drug-induced type 1 Brugada electrocardiographic pattern.

    Russo V, Caturano A, Migliore F, et al.

    Clinical research in cardiology : official journal of the German Cardiac Society 2025; doi:10.1007/s00392-025-02738-w.

    PMID: 40996547
  15. 15

    Robustness and relevance of predictive score in sudden cardiac death for patients with Brugada syndrome.

    Probst V, Goronflot T, Anys S, et al.

    European heart journal 2021; (42(17)):1687-1695 doi:10.1093/eurheartj/ehaa763.

    PMID: 33289793
  16. 16

    Validation of multiparametric approaches for the prediction of sudden cardiac death in patients with Brugada syndrome and electrophysiological study.

    Rodríguez-Mañero M, Baluja A, Hernández J, et al.

    Revista espanola de cardiologia (English ed.) 2022; (75(7)):559-567 doi:10.1016/j.rec.2021.07.007.

    PMID: 34479845
  17. 17

    Low-Dose Quinidine Effectively Reduced Shocks in Brugada Syndrome Patients with an Implantable Cardioverter Defibrillator: A Chinese Case Series Report.

    Shen T, Yuan B, Geng J, et al.

    Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc 2017; (22(1)) doi:10.1111/anec.12375.

    PMID: 27550400
  18. 18

    Shock Reduction With Long-Term Quinidine in Patients With Brugada Syndrome and Malignant Ventricular Arrhythmia Episodes.

    Anguera I, García-Alberola A, Dallaglio P, et al.

    Journal of the American College of Cardiology 2016; (67(13)):1653-1654 doi:10.1016/j.jacc.2016.01.042.

    PMID: 27150692
  19. 19

    Inappropriate implantable cardioverter-defibrillator shocks in Brugada syndrome: Pattern in primary and secondary prevention.

    Bonny A, Talle MA, Vaugrenard T, et al.

    Indian pacing and electrophysiology journal 2017; (17(1)):10-15 doi:10.1016/j.ipej.2016.10.010.

    PMID: 28401854
  20. 20

    Outcomes of catheter ablation in high-risk patients with Brugada syndrome refusing an implantable cardioverter defibrillator implantation.

    Li L, Ding L, Zhou L, et al.

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2023; (26(1)) doi:10.1093/europace/euad318.

    PMID: 37889958
  21. 21

    Long-Term Outcomes of Brugada Substrate Ablation: A Report from BRAVO (Brugada Ablation of VF Substrate Ongoing Multicenter Registry).

    Nademanee K, Chung FP, Sacher F, et al.

    Circulation 2023; (147(21)):1568-1578 doi:10.1161/CIRCULATIONAHA.122.063367.

    PMID: 36960730
  22. 22

    Can Artemisinin Be a Game Changer Even as an Antiarrhythmic Drug?

    Hwang J

    Korean circulation journal 2023; (53(4)):251-253 doi:10.4070/kcj.2023.0031.

    PMID: 37161683
  23. 23

    Catheter Ablation for Channelopathies: When Is Less More?

    Mehta A, Chandiramani R, Ghosh B, et al.

    Journal of clinical medicine 2024; (13(8)) doi:10.3390/jcm13082384.

    PMID: 38673656
  24. 24

    Pharmacological Therapy in Brugada Syndrome.

    Brodie OT, Michowitz Y, Belhassen B

    Arrhythmia & electrophysiology review 2018; (7(2)):135-142 doi:10.15420/aer.2018.21.2.

    PMID: 29967687
  25. 25

    Quinidine effective for the management of ventricular and atrial arrhythmias associated with Brugada syndrome.

    Halperin L, Mellor G, Talajic M, et al.

    HeartRhythm case reports 2018; (4(7)):270-272 doi:10.1016/j.hrcr.2018.01.008.

    PMID: 30023269
  26. 26

    Combined Right Ventricular Outflow Tract Epicardial and Endocardial Late Potential Ablation for Treatment of Brugada Storm: A Case Report and Review of the Literature.

    Saha SA, Krishnan K, Madias C, Trohman RG

    Cardiology and therapy 2016; (5(2)):229-243 doi:10.1007/s40119-016-0072-4.

    PMID: 27646458
  27. 27

    Brugada syndrome unmasked by fever: a comprehensive review of literature.

    Roomi SS, Ullah W, Abbas H, et al.

    Journal of community hospital internal medicine perspectives 2020; (10(3)):224-228 doi:10.1080/20009666.2020.1767278.

    PMID: 32850069
  28. 28

    Fever-Induced Brugada Syndrome Is More Common Than Previously Suspected: A Cross-Sectional Study from an Endemic Area.

    Rattanawong P, Vutthikraivit W, Charoensri A, et al.

    Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc 2016; (21(2)):136-41 doi:10.1111/anec.12288.

    PMID: 26178440

This page is for educational purposes only and does not replace professional medical advice. Always consult your cardiologist or electrophysiologist about your specific risks and whether an ICD is right for you.

Get notified when new evidence is published on Brugada syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.